Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis

Journal of Nuclear Medicine

Volumn 47, Issue 3, 2006, Pages 384-392

  Van Laere, Koenraad ^a   Casteels, Cindy ^a   De Ceuninck, Liesbet ^a   Vanbilloen, Bert ^b   Maes, Alex ^c   Mortelmans, Luc ^a   Vandenberghe, Wim ^a   Verbruggen, Alfons ^b   Dom, René ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Nuclear Medicine   (Belgium)

Author keywords

123I FP CIT; 99mTc ECD; Differential diagnosis; Discriminant analysis; Parkinsonism; SPECT

Indexed keywords

CYSTEINE ETHYL ESTER TC 99M; DOPAMINE TRANSPORTER; IOFLUPANE; N OMEGA FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE I 123; TRACER; UNCLASSIFIED DRUG; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; CYSTEINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M BICISATE; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DISCRIMINANT ANALYSIS; ESSENTIAL TREMOR; FEMALE; FOLLOW UP; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PERFUSION; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNIVERSITY HOSPITAL; VALIDATION STUDY; ALGORITHM; AUTOMATED PATTERN RECOGNITION; BRAIN; CLASSIFICATION; COMPUTER ASSISTED DIAGNOSIS; EVALUATION; IMAGE ENHANCEMENT; METABOLISM; METHODOLOGY; PARKINSON DISEASE; REPRODUCIBILITY; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING;

ALGORITHMS; BRAIN; CYSTEINE; DIAGNOSIS, DIFFERENTIAL; DISCRIMINANT ANALYSIS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MALE; ORGANOTECHNETIUM COMPOUNDS; PARKINSON DISEASE; PATTERN RECOGNITION, AUTOMATED; PERFUSION; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 33645993639     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet. 2004;363:1783-1793.
2. Chen JJ, Swope DM. Essential tremor: diagnosis and treatment. Pharmacotherapy. 2003;23:1105-1122.
3. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
4. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology. 2001;57:1497-1499.
5. Piccini P, Whone A. Functional brain imaging in the differential diagnosis of Parkinson's disease. Lancet Neurol. 2004;3:284-290.
6. Thobois S, Jahanshahi M, Pinto S, Frackowiak R, Limousin-Dowsey P. PET and SPECT functional imaging studies in parkinsonian syndromes: from the lesion to its consequences. Neuroimage. 2004;23:1-16.
7. 123I]-FP-CIT study group. Mov Disord. 2000;15:503-510.
8. Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism: Parkinson Study Group. Neurology. 2000;55:1540-1547.
9. Rakshi JS, Uema T, Ito K, et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease: A 3D [F-18]dopa-PET study. Brain. 1999;122:1637-1650.
10. Brooks DJ. PET studies on the function of dopamine in health and Parkinson's disease. Ann N Y Acad Sci. 2003;991:22-35.
11. 123I]Beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord. 2000;15:1158-1167.
12. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci. 2003;24:149-150.
13. Antonini A, Leenders KL, Vontobel P, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain. 1997;120:2187-2195.
14. Schwarz J, Oertel WH, Tatsch K. Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-dopa. J Nucl Med. 1996;37:1112-1115.
15. Knudsen GM, Karlsborg M, Thomsen G, et al. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging. 2004;31:1631-1638.
16. 99mTc-ECD brain perfusion SPET allows accurate differentiation between healthy volunteers, multiple system atrophy and idiopathic Parkinson's disease. Eur J Nucl Med Mol Imaging. 2003;30:16-24.
17. 18F-fluorodeoxyglucose and positron emission tomography. Neurology. 1995;45:1995-2004.
18. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry. 2002;73:517-523.
19. Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage. 2005;26:912-921.
20. Jankovic J. Essential tremor: clinical characteristics. Neurology. 2000;54 (11 suppl 4):S21-S25.
21. Quinn N. Multiple system atrophy: the nature of the beast. J Neurol Neurosurg Psychiatry. 1989;52(suppl):78-89.
22. Wenning GK, Benshlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical-features and natural-history of multiple system atrophy: an analysis of 100 cases. Brain. 1994;117:835-845.
23. Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry. 2000;68:434-440.
24. Litvan I, Agid Y, Jankovic J, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology. 1996;46:922-930.
25. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology. 1996;47:1113-1124.
26. Efron B. Estimating the error rate of a prediction rule: improvements on cross-validation. J Am Stat Assoc. 1983;78:316-331.
27. 123I]β-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain. 2005;128(part 7):1605-1612.
28. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology. 2005;64:208-215.
29. Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol. 2003;184(suppl 1):S68-S79.
30. Kortekaas R, Leenders KL, van Oostrom JC, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. 2005;57:176-179.
31. Gu XH, Zong R, Kula NS, Baldessarini RJ, Neumeyer JL. Synthesis and biological evaluation of a series of novel N- or O-fluoroalkyl derivatives of tropane: potential positron emission tomography (PET) imaging agents for the dopamine transporter. Bioorg Med Chem Lett. 2001;11:3049-3053.
32. Eidelberg D, Takikawa S, Moeller JR, et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol. 1993;33:518-527.
33. De Volder AG, Francart J, Laterre C, et al. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol. 1989;26:239-247.
34. 18F] fluorodeoxyglucose method. Ann Neurol. 1984;15:419-424.
35. Mentis MJ, McIntosh AR, Perrine K, et al. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. Am J Psychiatry. 2002;159:746-754.
36. Acton PD, Mozley PD, Kung HF. Logistic discriminant parametric mapping: a novel method for the pixel-based differential diagnosis of Parkinson's disease. Eur J Nucl Med. 1999;26:1413-1423.
37. Eidelberg D, Moeller JR, Kazumata K, et al. Metabolic correlates of pallidal neuronal activity in Parkinson's disease. Brain. 1997;120:1315-1324.
38. 18F-FDG. Ann Nucl Med. 1997;11:251-257.
39. 99mTc HmPAO SPECT data. J Neurol Neurosurg Psychiatry. 2000;69:661-663.
40. Van Laere K, Koole M, D'Asseler Y, et al. Automated stereotactic standardization of brain SPECT receptor data using single-photon transmission images. J Nucl Med. 2001;42:361-375.